Brian J. Blaser will lead the diagnostics division representing more than 70 IVD manufacturers.
AdvaMed has appointed Brian Blaser, president and CEO of QuidelOrtho, as the new chair of the AdvaMedDx Division Board of Directors. Blaser succeeds Thierry Bernard, CEO of QIAGEN, in the role.
AdvaMedDx represents more than 70 manufacturers of in vitro diagnostic tests used in patient care. Blaser will serve a two-year term beginning this month, leading the division during a period of significant advancement in molecular testing, artificial intelligence, and point-of-care technologies.
“Diagnostic tests are essential to timely diagnoses and appropriate patient care,” says Scott Whitaker, AdvaMed president and CEO, in a release. “The AdvaMedDx division drives the advocacy necessary to ensure patients have full access to the range of tests available to diagnose illness quickly and precisely and inform the right course of treatment.”
Blaser emphasized his commitment to regulatory and reimbursement policy advancement in his new role. “I’m honored to serve as AdvaMedDx board chair and to work alongside the division’s member companies to advance our shared priorities,” he says in a release. “I’m also committed to advancing a regulatory landscape that keeps pace with innovation and reimbursement policies enabling patient care.”
The leadership transition comes as the diagnostics industry continues to evolve with new technologies that are changing disease detection and monitoring approaches. According to AdvaMedDx, in vitro diagnostic tests influence 70% of all healthcare decisions.
“AdvaMedDx is fortunate to represent the leading in vitro diagnostic test makers,” says Zach Rothstein, executive director of AdvaMedDx, in a release. “Our division reflects the expertise and vision of those creating the tests that influence 70 percent of all health care decisions.”
Rothstein praised both the incoming and outgoing leadership for their understanding of the essential role IVD tests play in medical care. “Brian and Thierry understand the essential role in vitro diagnostic tests play in medical care around the clock, and their leadership is vital to sustaining this critical, scientifically rigorous facet of our health care system,” he says in a release.
Whitaker thanked Bernard for his service as the outgoing chair, noting his “exemplary service over an extended term as AdvaMedDx board chair.”
ID 17656381 © Deepfrog17 | Dreamstime.com
